Hong Kong Software Stock News

CEO transition puts China Mobile (SEHK:941) in focus China Mobile (SEHK:941) is back on investors’ radar after the Board announced that Chief Executive Officer and Executive Director Mr. He Biao resigned due to a work reassignment, effective 12 February 2026. The company confirmed Mr. He’s departure involves no disagreement with the Board. However, leadership changes of this level often prompt investors to revisit expectations for management continuity, capital allocation, and long term...

Profit warning centers investor attention on Skyworth Group Skyworth Group (SEHK:751) has issued new earnings guidance for 2025, flagging an expected 30% drop in annual profit versus 2024. This immediately puts the focus on how its different business segments are holding up. See our latest analysis for Skyworth Group. Despite the profit warning, Skyworth Group’s share price has moved sharply higher in recent months, with an 87.76% 90 day share price return and a very large 1 year total...

Wondering whether Meituan at HK$81.40 is starting to look priced for pessimism or opportunity? This article walks you through what the current market price might be implying about the business. The stock has seen a 0.8% decline over the last 7 days, a 16.6% decline over 30 days, a 22.2% decline year to date, and a 48.7% decline over 1 year, with a 40.2% decline over 3 years and a 77.5% decline over 5 years. These moves have kept Meituan firmly in focus for investors looking at large Chinese...

Guoco Group (SEHK:53) has just posted its H1 2026 scorecard, with the latest half-year context framed by H2 2025 revenue of about US$1.5b, basic EPS of US$0.87 and net income of US$283.1m. Over recent halves the group has reported revenue of US$1.3b in H2 2024, US$1.6b in H1 2025 and then US$1.5b in H2 2025. Over the same periods, basic EPS moved from US$0.84 to US$0.71 and then to US$0.87. This sets up a story where improving net margin and that HK$1.9b one off gain leave overall...

Easy Smart Group Holdings (SEHK:2442) has posted its H1 2026 scorecard with trailing 12 month revenue of HK$270.1 million and a basic EPS loss of HK$0.0191, keeping the focus squarely on whether margins can stop bleeding. The company has seen revenue move from HK$359.2 million with EPS of HK$0.0328 in H1 2025 to HK$314.5 million with an EPS loss of HK$0.0012 in H2 2025 and then to HK$270.1 million with a wider EPS loss of HK$0.0191 on a trailing 12 month basis, so investors are likely to read...

Why the latest irpagratinib trial step matters for Abbisko Cayman (SEHK:2256) Abbisko Cayman (SEHK:2256) has moved its FGFR4 inhibitor irpagratinib into a global Phase I study in the United States. This milestone builds on earlier regulatory designations and clinical data disclosures. See our latest analysis for Abbisko Cayman. Despite the irpagratinib milestones, Abbisko Cayman’s share price has eased recently, with a 30 day share price return of a 7.28% decline and a 90 day share price...

HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China. See our latest analysis for HBM Holdings. The Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder...

Hua Hong Semiconductor (SEHK:1347) is in focus after reporting fourth quarter 2025 results that moved back to net profitability and issuing first quarter 2026 revenue guidance that gives investors clearer near term expectations. See our latest analysis for Hua Hong Semiconductor. Those results sit against a mixed recent trading pattern, with a 4.51% 1 day share price return and a 37.91% 90 day share price return. The 1 year total shareholder return of 137.39% highlights how strongly sentiment...

CARsgen Therapeutics Holdings (SEHK:2171) has entered new cooperation agreements to build a commercial CAR T-cell manufacturing base in Shanghai’s Jinshan District, supporting its existing therapies, late-stage candidates and future allogeneic products. See our latest analysis for CARsgen Therapeutics Holdings. The cooperation news lands as CARsgen’s share price sits at HK$16.14, with a 1-day share price return of 3.33% and 7-day share price return of 7.10%. The 1-year total shareholder...

InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs. See our latest analysis for InnoCare Pharma. The new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...

CEO retirement and board changes put ASMPT in focus ASMPT (SEHK:522) has drawn investor attention after announcing that long serving Group CEO Robin Gerard Ng Cher Tat will retire and not seek re election as director, with Executive Director Guenter Walter Lauber also set to depart after the upcoming AGM. See our latest analysis for ASMPT. The leadership changes come as ASMPT’s share price has moved to HK$110.3, with a 5.15% 1 day and 50.48% 90 day share price return, while the 1 year total...

Why Lenovo Group Stock Is On Investors’ Radar Today Lenovo Group (SEHK:992) has drawn investor attention after a period where the share price has moved higher over the past month but remains lower over the past year. With the stock recently closing at HK$9.37 and multi year returns still positive, many holders are reassessing how its current valuation lines up with the company’s earnings profile and growth in both revenue and net income. See our latest analysis for Lenovo Group. Recent moves...

China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs. See our latest analysis for China Medical System Holdings. The stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...

If you are wondering whether BYD at around HK$100.10 is a bargain or just fairly priced, you are not alone. That is exactly what this article will help you unpack. The stock has returned 2.4% over the last 7 days, 0.5% over 30 days, 1.4% year to date, but is still showing a 21.9% decline over 1 year while sitting on gains of 43.8% over 3 years and 45.6% over 5 years. Recent headlines around BYD have focused on its expanding presence in electric vehicles and batteries, as well as ongoing...

China Resources Land (SEHK:1109) has released its January 2026 operating update, reporting contracted sales of about RMB 11.65b and recurring revenue of RMB 4.51b, giving investors a fresh monthly read on business activity. See our latest analysis for China Resources Land. The January update comes after a solid stretch of gains, with a 1-month share price return of 10.42% and year to date share price return of 12.41%. The 1-year total shareholder return of 31.18% suggests momentum has been...

Tencent Holdings after recent share price weakness Tencent Holdings (SEHK:700) has seen its share price fall around 12% over the past month and about 16% over the past 3 months, prompting investors to reassess what they are paying for its earnings and growth profile. See our latest analysis for Tencent Holdings. Looking beyond the recent pullback, Tencent Holdings’ 30 day share price return of 12.27% and year to date share price return of 16.21% both point to fading momentum, even though the...

Global markets have recently experienced volatility, with U.S. stocks declining amid concerns over AI disruptions and a mixed economic outlook from various regions. Despite these fluctuations, investors continue to seek opportunities that balance value and growth potential. Penny stocks, though an outdated term, remain relevant for those interested in smaller or newer companies with strong financials that may offer significant returns. In this article, we explore three such penny stocks that...

Insilico Medicine Cayman TopCo announced a new partnership with China Medical System Holdings SEHK:3696 to collaborate on AI powered drug discovery and development. The company also nominated ISM5059, an NLRP3 targeted drug candidate discovered using its AI platform, for preclinical development. These updates follow recent FDA IND approval for another AI created drug in Insilico Medicine's pipeline. For you as an investor, these moves sit at the intersection of AI and pharmaceuticals, where...

Q Technology (Group) (SEHK:1478) has released its January 2026 operating update, reporting monthly sales volumes of 44,071,000 camera modules and 19,741,000 fingerprint recognition modules. This provides investors with a fresh data point on current demand. See our latest analysis for Q Technology (Group). At a share price of HK$8.82, Q Technology (Group) has a 1-year total shareholder return of 12.98% and a 3-year total shareholder return of 86.90%, even though its 30-day share price return...

As global markets grapple with concerns over AI disruptions and mixed economic signals, Asian markets have shown resilience, with Japan's stock indices experiencing significant gains following political developments. In this environment, dividend stocks in Asia offer a compelling option for investors seeking steady income streams; these stocks can provide a buffer against market volatility while potentially yielding attractive returns.

If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. The stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity. Recent trading interest has been shaped by ongoing attention on the biotech and...

Sinofert Holdings Limited has announced that, effective 13 February 2026, Mr. Su Fu resigned as non-executive director and Chairman, with industry veteran Mr. Zhang Xuegong appointed as executive director, Chairman of the Board and head of the strategy committee. This leadership shift brings the group’s fertilizer, chemical and seed businesses under a chairman who previously held senior roles across Sinochem’s agricultural value chain, potentially reshaping how Sinofert aligns with its...

Minth Group (SEHK:425) has drawn fresh attention after announcing two North American joint ventures: one focused on aluminum body frame parts in Canada and another on humanoid robot joint modules in the United States. See our latest analysis for Minth Group. The recent North American joint venture announcements align with strong momentum in the stock, with a 36.28% 1-month share price return and a very large 1-year total shareholder return, suggesting investors are reassessing Minth Group's...

AIA Group Limited has appointed Ms. Shulamite N K Khoo and Mr. Ku Man as Independent Non-executive Directors to its board, effective 5 February 2026, drawing on their extensive experience across Asian financial services, technology and human capital management. The addition of Ms. Khoo, a former AIA Group Chief Human Resources Officer, and Mr. Ku, Chairman of WeBank, strengthens the board’s governance depth and digital financial expertise at a time when regional insurers are adapting to...